Model‐Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis

The selective T‐cell costimulation modulator abatacept is approved for treatment of adult rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA; 6‐17 years [intravenous] and 2‐17 years [subcutaneous]). An extrapolation approach was taken to determine subcutaneous weight‐tie...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Yash, Passarell, Julie A., Roy, Amit, Murthy, Bindu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pediatric Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048692/
https://www.ncbi.nlm.nih.gov/pubmed/33284480
http://dx.doi.org/10.1002/jcph.1797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048692/
https://www.ncbi.nlm.nih.gov/pubmed/33284480
http://dx.doi.org/10.1002/jcph.1797

Ejemplares similares